NEUMORA THERAPEUTICS INC (NMRA:NASDAQ)
$1.68 0.02 (1.2048%)
Analysed NEUMORA THERAPEUTICS INC (NMRA:NASDAQ) News Sources
Sector Update: Healthcare Stocks Softer Monday Afternoon
15-06-2026
yahoo.com
Sector Update: Healthcare Stocks Softer Late Afternoon
15-06-2026
yahoo.com
Neumora depression drug fails; EnGene to cut 50% of staff
16-06-2026
biopharmadive.com
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
16-06-2026
yahoo.com
Three pivotal MDD trial failures for Neumora lead to staffing cuts
16-06-2026
clinicaltrialsarena.com
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data
17-06-2026
yahoo.com
LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential
02-07-2026
yahoo.com
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy
07-07-2026
yahoo.com
Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation
11-07-2026
yahoo.com
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
27-07-2026
yahoo.com
What is the current price of NEUMORA THERAPEUTICS INC (NMRA:NASDAQ)?
The current price of NEUMORA THERAPEUTICS INC (NMRA:NASDAQ) is $1.68.
NEUMORA THERAPEUTICS INC (NMRA:NASDAQ) absolute price change since previous trading day?
The absolute price change of NEUMORA THERAPEUTICS INC (NMRA:NASDAQ) since the previous trading day is $0.02.
NEUMORA THERAPEUTICS INC (NMRA:NASDAQ) percentage price change since previous trading day?
The percentage price change of NEUMORA THERAPEUTICS INC (NMRA:NASDAQ) since the previous trading day is 1.2048%.
What is the most recent average sentiment score for NEUMORA THERAPEUTICS INC (NMRA:NASDAQ)?
The most recent average sentiment score for NEUMORA THERAPEUTICS INC (NMRA:NASDAQ) is 44 out of 100.
What is the most recent average sentiment for NEUMORA THERAPEUTICS INC (NMRA:NASDAQ)?
The most recent sentiment for NEUMORA THERAPEUTICS INC (NMRA:NASDAQ) is .
SEC-8K** Filing Available For NEUMORA THERAPEUTICS INC (NMRA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.